216 related articles for article (PubMed ID: 28584105)
1. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake.
Chicca A; Nicolussi S; Bartholomäus R; Blunder M; Aparisi Rey A; Petrucci V; Reynoso-Moreno IDC; Viveros-Paredes JM; Dalghi Gens M; Lutz B; Schiöth HB; Soeberdt M; Abels C; Charles RP; Altmann KH; Gertsch J
Proc Natl Acad Sci U S A; 2017 Jun; 114(25):E5006-E5015. PubMed ID: 28584105
[TBL] [Abstract][Full Text] [Related]
2. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J
Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246
[TBL] [Abstract][Full Text] [Related]
3. Evidence for bidirectional endocannabinoid transport across cell membranes.
Chicca A; Marazzi J; Nicolussi S; Gertsch J
J Biol Chem; 2012 Oct; 287(41):34660-82. PubMed ID: 22879589
[TBL] [Abstract][Full Text] [Related]
4. The antinociceptive triterpene β-amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis without directly targeting cannabinoid receptors.
Chicca A; Marazzi J; Gertsch J
Br J Pharmacol; 2012 Dec; 167(8):1596-608. PubMed ID: 22646533
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoid biosynthesis and inactivation, from simple to complex.
Muccioli GG
Drug Discov Today; 2010 Jun; 15(11-12):474-83. PubMed ID: 20304091
[TBL] [Abstract][Full Text] [Related]
6. Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: a critical revisitation.
Ortar G; Cascio MG; Moriello AS; Camalli M; Morera E; Nalli M; Di Marzo V
Eur J Med Chem; 2008 Jan; 43(1):62-72. PubMed ID: 17452063
[TBL] [Abstract][Full Text] [Related]
7. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
Pertwee RG
Proc Nutr Soc; 2014 Feb; 73(1):96-105. PubMed ID: 24135210
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
Giuffrida A; Beltramo M; Piomelli D
J Pharmacol Exp Ther; 2001 Jul; 298(1):7-14. PubMed ID: 11408519
[TBL] [Abstract][Full Text] [Related]
9. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders.
Iannotti FA; Di Marzo V; Petrosino S
Prog Lipid Res; 2016 Apr; 62():107-28. PubMed ID: 26965148
[TBL] [Abstract][Full Text] [Related]
10. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors.
Moreira FA; Kaiser N; Monory K; Lutz B
Neuropharmacology; 2008 Jan; 54(1):141-50. PubMed ID: 17709120
[TBL] [Abstract][Full Text] [Related]
11. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites.
Turcotte C; Chouinard F; Lefebvre JS; Flamand N
J Leukoc Biol; 2015 Jun; 97(6):1049-70. PubMed ID: 25877930
[TBL] [Abstract][Full Text] [Related]
12. Transport of endocannabinoids across the plasma membrane and within the cell.
Fowler CJ
FEBS J; 2013 May; 280(9):1895-904. PubMed ID: 23441874
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
14. Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses.
Busquets-Garcia A; Puighermanal E; Pastor A; de la Torre R; Maldonado R; Ozaita A
Biol Psychiatry; 2011 Sep; 70(5):479-86. PubMed ID: 21684528
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs.
Batista LA; Gobira PH; Viana TG; Aguiar DC; Moreira FA
Behav Pharmacol; 2014 Sep; 25(5-6):425-33. PubMed ID: 25083569
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study.
Wiskerke J; Irimia C; Cravatt BF; De Vries TJ; Schoffelmeer AN; Pattij T; Parsons LH
ACS Chem Neurosci; 2012 May; 3(5):407-17. PubMed ID: 22860210
[TBL] [Abstract][Full Text] [Related]
17. Does the hydrolysis of 2-arachidonoylglycerol regulate its cellular uptake?
Fowler CJ; Ghafouri N
Pharmacol Res; 2008 Jul; 58(1):72-6. PubMed ID: 18675915
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Bortolato M; Campolongo P; Mangieri RA; Scattoni ML; Frau R; Trezza V; La Rana G; Russo R; Calignano A; Gessa GL; Cuomo V; Piomelli D
Neuropsychopharmacology; 2006 Dec; 31(12):2652-9. PubMed ID: 16541083
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
[TBL] [Abstract][Full Text] [Related]
20. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
